{"name":"Premier Specialists, Australia","slug":"premier-specialists-australia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"isotretinoin (Roaccutane)","genericName":"isotretinoin (Roaccutane)","slug":"isotretinoin-roaccutane","indication":"Severe nodular acne unresponsive to conventional therapy","status":"marketed"}]}],"pipeline":[{"name":"isotretinoin (Roaccutane)","genericName":"isotretinoin (Roaccutane)","slug":"isotretinoin-roaccutane","phase":"marketed","mechanism":"Isotretinoin is a potent retinoid that reduces sebaceous gland size and sebum production, and has anti-inflammatory and anti-proliferative effects on skin cells.","indications":["Severe nodular acne unresponsive to conventional therapy","Acne with high risk of permanent scarring"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQYUE2NGd1d2NYaXJGVTIzRDFpTHpvcE1vZXFGUFJIQ29jNUlseEJvcF9uT2ZpbDY4ZXBTT2E4OGEzWkREWUZ1ZzRxR2FXLWR3VWxyMF9UMDZCaGNkczVVbUhGLUJKM2pEY0NMc0dma015a2trRGd1R0JKbHQ3ekczWkROTmM3b1pfR1BrOVZIRWt3c2ViLUFOZ3V1SlRtUTdNUERIeTJpYThLa19RbENmbXZHVElia2pTTWQzZzIwbk83QkpWcjI2UDAyaGFQd3VMdzdwREpKVUttNFRYd2xlQmdyRG00aVFZYUE?oc=5","date":"2025-09-22","type":"deal","source":"Capital Brief","summary":"How the fight over $672m pharma deal became a 'watershed' moment for ASX takeovers - Capital Brief","headline":"How the fight over $672m pharma deal became a 'watershed' moment for ASX takeovers","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-30","type":"pipeline","source":"Adelaide Now","summary":"$672m pharma giant best in the business - Adelaide Now","headline":"$672m pharma giant best in the business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPZkZxZGQ5ejZiSktpZWRDOXM3TUJiYnFsUTVyazBLWFNQMU1sb1NFMlMxbktUb0xMTzZucHlIeGxZRG50cWEyOXdkd3dKTXpWekV0NEljc3lvUWlrZVY2c2ZTdTFSOGw2SVNpTHd2b2o1bXZ5cTFqeFpmRW02cEZhNTNCVl9BVlNIdDNPa2pjRjJXampUQjlka1FUN0FleUlVenNMZGptaW84NUF5dmRFU1A2WVlNUQ?oc=5","date":"2018-02-12","type":"deal","source":"Contract Pharma","summary":"PCI Acquires Pharmaceutical Packaging Professionals - Contract Pharma","headline":"PCI Acquires Pharmaceutical Packaging Professionals","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}